Cytosorbents
Open
$0.40
Prev. Close
$0.40
High
$0.40
Low
$0.40
Market Snapshot
$25.07M
-2.1
-0.38
$32.97M
129
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 129 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 129 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Recently from Cashu
Cytosorbents: Innovative Solutions in Blood Purification for Critical Care and Beyond
Please provide the content you'd like me to summarize.
CytoSorbents Prepares for FDA Decision on DrugSorb™-ATR Amid Strong Sales and Growth
CytoSorbents Advances Blood Purification Solutions Amid Regulatory Anticipation CytoSorbents Corporation, a leader in blood purification technologies for critical care and cardiac surgery, prepares fo…
CytoSorbents Showcases Blood Purification Innovations at Jefferies Global Healthcare Conference
CytoSorbents Advances Blood Purification Technologies at Upcoming Healthcare Conference CytoSorbents Corporation, a leader in the field of blood purification, prepares to showcase its innovative solut…
Cytosorbents Showcases Blood Purification Innovations at Jefferies Global Healthcare Conference
CytoSorbents Advances Blood Purification Technologies in Critical Care CytoSorbents Corporation, a leader in blood purification technologies, is poised to showcase its innovations at the upcoming Jeff…